Recently, the State Key Laboratory of Respiratory Diseases, jointly established by the Guangzhou Institute of Biomedicine and Health of the Chinese Academy of Sciences and Guangzhou Medical University, and Tsinghua University have successfully cooperated to separate the first case from the macaques by single cell cloning and other technologies. A highly potent monoclonal neutralizing antibody against Ebola virus infection. The study was published online May 17 in Scientific Reports on the topic of Potent neutralizing monoclonal antibodies against Ebola virus infection ("Efficient monoclonal neutralizing antibodies against Ebola virus infection"). Zhang Linqi, a professor at Tsinghua University, and Chen Ling, a researcher at the State Key Laboratory of Respiratory Diseases, and Qiu Xianguo, a professor at the Canadian Public Health Bureau, are co-authors of the article. Dr. Zhang Wei from Tsinghua University, Dr. Gui Yan from Tsinghua University, and Dr. Niu Xuefeng from the State Key Laboratory of Respiratory Diseases were listed as the first authors of the article.
The Ebola virus is one of the most deadly infectious viruses known to humans to date, with an average mortality rate of around 40%. Founded in the Democratic Republic of the Congo in 1976, it has been erupting and prevalent in small areas of Central African countries and regions. Beginning in the spring of 2014, the Ebola outbreak suddenly broke out in Guinea, Liberia and Sierra Leone in western Africa, causing a catastrophic blow to people's lives, economic development and social stability, and proposing public health and safety in the new situation. An unprecedented challenge.
Fundamentally curbing the outbreak and epidemic of new infectious diseases such as Ebola depends on effective and accessible medical interventions. But so far, there are no clinically specific treatments and preventive vaccines for Ebola. The project team's scientific and technical personnel started the early stage of the Ebola virus in West Africa in early 2014, and took the lead in carrying out research work on Ebola virus in China. It established and verified the immunization of Chinese macaques with high affinity to humans. A platform for screening high-affinity neutralizing antibodies against pathogens by single-cell cloning techniques using peripheral blood lymphocytes from immunized macaques as a source. The antibody obtained by the platform technology is gradually matured due to multiple antigen stimulation by the immune cells, and the high frequency mutation of the antibody gene finally increases the affinity, thereby blocking the infection of the pathogen more effectively; on the other hand, due to the macaque and the human The high homology of the antibody gene, and the resulting rhesus antibody variable region and the human antibody constant region combined into a chimeric antibody, are completely similar to the pure human antibody, making its clinical application prospects relative to other animals such as mice. Antibodies from rabbits and other sources are more open. In the case of new outbreaks of infectious diseases and without the provision of immune cells for recovery of high-potency neutralizing antibodies, the use of this strategy to rapidly address emerging new infectious diseases can quickly find candidate neutralizing antibodies for clinical treatment.
Key Box And Cash Box,Steel Cash Safe,Small Tin Key Box,Metal Cash Coin Box
Hebei Hupai Aodi Cabinet Industry Co.,Ltd. , https://www.hupaiaodi.com